Relatlimab and nivolumab provide greater survival benefit for advanced melanoma
1. In patients with untreated metastatic or unresectable melanoma, the combination of Relatlimab and Nivolumab was associated with greater progression-free ...
Tag: Nivolumab
#VisualAbstract: Immune checkpoint inhibitors are equally effective for younger and older patients with relapsed or metastatic head and neck squamous cell carcinomas
Click to read this study in the European Journal of Cancer.
#VisualAbstract: Taxane monotherapy may be more effective for patients with recurrent or metastatic head and neck cancer and prior nivolumab exposure
Click to read this study in the European Journal of Cancer.
#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males
Click to read this study in JAMA Network Open.
Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma
1. The median overall survival for nivolumab was 16.4 months and for sorafenib was 14.7 months 2. Patients receiving nivolumab ...
Nivolumab is a potential treatment option for patients with relapsing malignant mesothelioma
1. Overall survival was 6.9 months in the placebo group and 10.2 months in the nivolumab group. 2. Progression free ...
#VisualAbstract: Greater immunosuppression is associated with worse outcomes in patients with advanced melanoma receiving ipilimumab and anti-PD-1 therapy
Click to read the study in the European Journal of Cancer.
Adjunctive nivolumab reduces risk of death and progression of gastric adenocarcinoma compared to chemotherapy alone
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.